Pasithea Therapeutics Corp (KTTA) has a current Price-to-Book (P/B) ratio of 0.73. Compared to its 3-year average P/B ratio of 0.30, the current P/B ratio is approximately 138.77% higher. Relative to its 5-year average P/B ratio of 1.44, the current P/B ratio is about -49.53% higher. Pasithea Therapeutics Corp (KTTA) has a Forward Free Cash Flow (FCF) yield of approximately -45.99%. Compared to its 3-year average FCF yield of -261.66%, the current FCF yield is approximately -82.42% lower. Relative to its 5-year average FCF yield of -180.11%, the current FCF yield is about -74.47% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for KTTA competitors is 44.81, providing a benchmark for relative valuation. Pasithea Therapeutics Corp Corp (KTTA.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of KTTA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of KTTA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is KTTA currently overvalued or undervalued?

What is Pasithea Therapeutics Corp (KTTA) fair value?

KTTA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Pasithea Therapeutics Corp (KTTA) is between NaN to NaN according to relative valuation method.

How does KTTA's valuation metrics compare to the industry average?

The average P/S ratio for KTTA's competitors is 44.81, providing a benchmark for relative valuation. Pasithea Therapeutics Corp Corp (KTTA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Pasithea Therapeutics Corp (KTTA) as of Mar 03 2026?

As of Mar 03 2026, Pasithea Therapeutics Corp (KTTA) has a P/B ratio of 0.73. This indicates that the market values KTTA at 0.73 times its book value.

What is the current FCF Yield for Pasithea Therapeutics Corp (KTTA) as of Mar 03 2026?

As of Mar 03 2026, Pasithea Therapeutics Corp (KTTA) has a FCF Yield of -45.99%. This means that for every dollar of Pasithea Therapeutics Corp's market capitalization, the company generates -45.99 cents in free cash flow.

What is the current Forward P/E ratio for Pasithea Therapeutics Corp (KTTA) as of Mar 03 2026?

As of Mar 03 2026, Pasithea Therapeutics Corp (KTTA) has a Forward P/E ratio of -1.34. This means the market is willing to pay $-1.34 for every dollar of Pasithea Therapeutics Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Pasithea Therapeutics Corp (KTTA) as of Mar 03 2026?

As of Mar 03 2026, Pasithea Therapeutics Corp (KTTA) has a Forward P/S ratio of 0.00. This means the market is valuing KTTA at $0.00 for every dollar of expected revenue over the next 12 months.

KTTA Valuation